Newsfilter article unlocker
Enter Newsfilter article ID in the field below. Example: https://newsfilter.io/articles/39be1bef03e66cdc886c08a2a6319c47
ProKidney Corp. (NASDAQ:PROK) Citi's Biopharma Back to School Conference September 3, 2025 10:30 AM EDT
Company Participants
Bruce Culleton - CEO & Director
Ethan Holdaway
Conference Call Participants
Yigal Nochomovitz - Citigroup Inc., Research Division
Presentation
Yigal Nochomovitz
Director and SMid Cap Biotech Analyst
Welcome, everyone, to the next session of the Citi's Biopharma back-to-school Summit. So we are literally back to school, checking up on all the companies. So the next one is it's my pleasure to introduce the management from ProKidney. We have Bruce Culleton, CEO; and Ethan Holdaway, who is the Head of the Investor Relations group. So welcome. I'm Yigal Nochomovitz. And for those of you in the room, if you're interested in asking questions, just chime in, there's microphones and also welcome to everyone listening on the webcast.
Question-and-Answer Session
Yigal Nochomovitz
Citigroup Inc., Research Division
So Bruce, obviously, you've had a very busy summer with some pretty important data that sent the stock up quite a lot, actually. So tell us about the data, tell us about the platform, I guess, maybe to start with and how you got to this point?
Bruce Culleton
CEO & Director
Sure. So first, Yigal, thanks for having us here. We appreciate the opportunity to talk and answer any questions as well. So you're right, we had a busy summer. We announced the results of one of our Phase II trial, top line results in July. And just as a background, ProKidney is an autologous cell therapy company. We have a single asset that's called Rilparencel. It's directed at preserving kidney function in patients who have type 2 diabetes and advanced chronic kidney disease.
So our company's headquarters are in North Carolina, where a manufacturing -- it's in Winston-Salem. We have some clinical office and an R&D office in Raleigh. And we have
